Time-of-day administration of immune checkpoint inhibitors: current clinical evidence and future directions for breast cancer
- 1 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 38 (6) , 471-478
Abstract
Purpose of review: Immune checkpoint inhibitors (ICIs) are increasingly used in breast cancer, particularly in triple-negative breast cancer. This review summarizes the biologic rationale and emerging clinical evidence for time-of-day ICI administration and discusses its implications for breast cancer. Recent findings: Circadian rhythms provide a biologic rationale for time-dependent immunotherapy efficacy. Several retrospective studies across multiple tumor types have suggested associations between earlier ICI administration and improved outcomes, although findings remain inconsistent. Breast cancer-specific data are expanding but remain heterogeneous, with signals varying by treatment setting, endpoint, timing definition, and tumor immune contexture. These findings suggest that treatment timing should be interpreted in the context of the broader treatment platform in which immunotherapy is delivered, including concomitant chemotherapy and supportive medications, as well as host circadian state and tumor immune contexture. An ongoing prospective study aims to integrate circadian, systemic immune, and tumor-based assessments to elucidate the biological and clinical relevance of treatment timing in breast cancer. Summary: Current evidence does not establish an optimal infusion window for breast cancer treatment. Prospective studies integrating clinical outcomes with circadian, systemic immune, and tumor-based analyses are needed to determine whether treatment timing can be developed into a biologically informed strategy.Keywords
This publication has 25 references indexed in Scilit:
- Time-of-Day Immunotherapy Administration and Outcomes in Advanced CancersJAMA Network Open, 2026
- 151TiP CIRCADIAN: Circadian rhythm impact on triple-negative breast cancer (TNBC) response to neoadjuvant immunotherapy – A feasibility randomized trialESMO Open, 2025
- Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental studyEBioMedicine, 2025
- Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacyCell, 2024
- Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic studyEuropean Journal of Cancer, 2024
- Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysisESMO Open, 2024
- Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal studyThe Lancet Oncology, 2021
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune ResponsesImmunity, 2017
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014